• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Infect Chemother . Duration of infectious viral shedding in patients with mild to moderate COVID-19 treated with REGN-CoV2

tetano

Editor, Senior Moderator
J Infect Chemother


. 2022 Mar 22;S1341-321X(22)00092-7.
doi: 10.1016/j.jiac.2022.03.013. Online ahead of print.
Duration of infectious viral shedding in patients with mild to moderate COVID-19 treated with REGN-CoV2


Toshihito Nomura[SUP] 1 [/SUP], Hiroki Kitagawa[SUP] 2 [/SUP], Masaki Kakimoto[SUP] 3 [/SUP], Yuki Kaiki[SUP] 4 [/SUP], Tanuza Nazmul[SUP] 5 [/SUP], Daisuke Miyamori[SUP] 3 [/SUP], Keitaro Omori[SUP] 2 [/SUP], Norifumi Shigemoto[SUP] 6 [/SUP], Masanori Ito[SUP] 3 [/SUP], Takemasa Sakaguchi[SUP] 5 [/SUP], Hiroki Ohge[SUP] 2 [/SUP]



Affiliations

Abstract

Introduction: New treatment methods, such as REGN-CoV2, have been approved for patients with coronavirus disease (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, the effect of the drug on the duration of infectious viral shedding and viral mutations is unknown. In this study, we investigated the clinical efficacy of REGN-CoV2 treatment in patients with mild to moderate disease and compared its antiviral effects against different strains of SARS-CoV-2.
Methods: Viral culture and PCR testing were performed on the pharyngeal swabs collected from 28 patients with COVID-19 who were admitted and treated at Hiroshima University Hospital during the study period. Of these, 23 patients were treated with REGN-CoV2. The patients were classified into the REGN-CoV2(+) and REGN-CoV2(-) groups, and the clinical course was compared between the groups. The 50% inhibitory concentrations (IC[SUB]50[/SUB]) of REGN-CoV2 against the isolated virus strains were determined.
Results: After treatment with REGN-CoV2, the virus culture positivity rate was greatly reduced. The time to negative viral culture was significantly shorter in the REGN-CoV2(+) group than in the REGN-CoV2(-) group. In vitro evaluation of REGN-CoV2 against isolated virus strains also showed efficacy.
Conclusions: REGN-CoV2 treatment was effective in patients with mild COVID-19 and could shorten the period of infectious viral shedding. This may be an important factor in preventing the spread of infection. It may be possible to revise the isolation period for patients with mild disease treated with REGN-CoV2.

Keywords: COVID-19; Delta variant; REGN-CoV2; SARS-CoV-2; Viral shedding.
 
Back
Top Bottom